GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: LY-2495655 | LY2495655
                                 
                                                         
                            Compound class: 
                                                            Antibody
                                 
                                
                                    
                                        Comment: Landogrozumab is an investigational anti-myostatin, humanized, monoclonal antibody. 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                    Peptide sequences and structural information for this antibody are available from its IMGT/mAb-DB record. A BLAST protein search using the light and heavy chain variable regions of landogrozumab, identifies 100% matches with sequences patented in US7632499 B2 [2], and point towards clone 3-74/C1E4, as a preferred embodiment, taken forward for further anaylsis.  | 
                                    
| Bioactivity Comments | 
| Affinity data in the table below is that provided in [2], for clone 3-74/C1E4. | 
| Other ligands which bind to or alter the activity of this ligand | ||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||
                                                                    
                                                                     
  | 
                                                            ||||||||||||||||||||||||||||||||||||||||||||||